Resistance of <i>Fasciola hepatica</i> to triclabendazole and albendazole in sheep in Spain

Álvarez-Sánchez, M.A.; Jaime, R. C. M.; Pérez-García, J.; Rojo-Vázquez, F.A.

doi:10.1136/vr.159.13.424

Cited by 122 publications

(53 citation statements)

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since then, resistant populations have been reported in Ireland, the Netherlands (references in Fairweather, 2005), Spain (Á lvarez-Sánchez et al, 2006) and much of the UK, with mounting evidence suggesting that resistance is underestimated and spreading (Wolstenholme et al, 2004). The spread of resistance to the drug of choice creates a significant need for new strategies for fluke control.…”

Section: Introductionmentioning

confidence: 99%

Adult triclabendazole-resistantFasciola hepatica: morphological changes in the tegument and gut followingin vivotreatment with artemether in the rat model

O'Neill

Johnston²,

Halferty³

et al. 2009

J. Helminthol.

View full text Add to dashboard Cite

A study has been carried out to determine the morphological changes to the adult liver fluke, Fasciola hepatica after treatment in vivo with artemether. Rats were infected with the triclabendazole-resistant Sligo isolate of F. hepatica, dosed orally with artemether at a concentration of 200 mg/kg and flukes recovered at 24, 48 and 72 h post-treatment (p.t.). Surface changes were monitored by scanning electron microscopy and fine structural changes to the tegument and gut by transmission electron microscopy. Twenty-four hours p.t., the external surface showed minor disruption, in the form of mild swelling of the tegument. The tegumental syncytium and sub-tegumental tissues appeared relatively normal. Forty-eight and seventy-two hours p.t., disruption to the tegumental system increased, with isolated patches of surface blebbing and reduced production of secretory bodies by the tegumental cells being the main changes seen. The gastrodermal cells showed a relatively normal morphology 24 h p.t. By 48 h, large numbers of autophagic vacuoles and lipid droplets were present. Autophagy increased in magnitude by 72 h p.t. and substantial disruption to the granular endoplasmic reticulum was observed. Results from this study show that flukes treated in vivo with artemether display progressive and timedependent alterations to the tegument and gut. Disruption to the gut was consistently and substantially more severe than that to the tegument, suggesting that an oral route of uptake for this compound predominates. This is the first study providing ultrastructural information on the effect of an artemisinin compound against liver fluke.

show abstract

Section: Introductionmentioning

confidence: 99%

Adult triclabendazole-resistantFasciola hepatica: morphological changes in the tegument and gut followingin vivotreatment with artemether in the rat model

O'Neill

Johnston²,

Halferty³

et al. 2009

J. Helminthol.

View full text Add to dashboard Cite

show abstract

“…[21][22][23] However, in recent years F. hepatica has been reported to present resistance to TCBZ in various countries. [8][9][10][11][12]24 This study demonstrated that oxfendazole at 30 mg/kg acts efficaciously against F. hepatica in naturally infected sheep. Although the study was not designed to evaluate the safety or pharmacokinetics of this dosage of oxfendazole in sheep, the animals did not show any signs of toxicity.…”

Section: Discussionmentioning

confidence: 99%

“…6,7 Triclabendazole (TCBZ) is the current drug of choice; however, TCBZ resistance has already been reported in livestock farms across Europe, Australia, and some countries of South America. [8][9][10][11][12] Our group has extensive experience using a single oral dose of 30 mg/kg of oxfendazole to treat porcine cysticercosis (Taenia solium). To the best of our knowledge, this scheme has not been tested for trematode infections in field conditions.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of a Single Oral Dose of Oxfendazole against Fasciola hepatica in Naturally Infected Sheep

Gómez-Puerta

Gavidia

López-Urbina

et al. 2012

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

show abstract

“…Most recently, triclabendazole resistance has been reported in Spain (Alvarez-Sanchez et al, 2006;Fairweather, 2005;. Although triclabendazole resistance has not been reported in human infections thus far, it might just be a matter of time, as humans are likely to become infected with Fasciola metacercariae of animal origin (Coles, 2006).…”

Section: Introductionmentioning

confidence: 99%

Activity of artemether and OZ78 against triclabendazole-resistant Fasciola hepatica

Keiser

Utzinger

Vennerstrom

et al. 2007

Transactions of the Royal Society of Tropical Medicine and Hygi

View full text Add to dashboard Cite

SummaryTriclabendazole is the drug of choice against Fasciola hepatica infections in humans and animals. However, parasite resistance against triclabendazole is spreading in the veterinary field, and there are no drugs of comparable activity currently available for the treatment and control of fascioliasis. We investigated the efficacy of single oral doses of artemether and OZ78 against adult triclabendazole-resistant F. hepatica harboured in rats, and compared the results with triclabendazole administered at two different doses. Single oral doses of 100 mg/kg OZ78 and 200 mg/kg artemether resulted in worm burden reductions of 100%. Whereas a single 10 mg/kg dose of triclabendazole achieved a worm burden reduction of only 4.0%, a five-fold higher dose yielded a significant worm burden reduction of 60.9%. However, the lower dose of triclabendazole administered to rats harbouring a triclabendazole-sensitive F. hepatica isolate resulted in a worm burden reduction of 95.3%. Our findings confirm that artemether and OZ78 possess good fasciocidal properties, even against a triclabendazole-resistant F. hepatica isolate, and hence these drugs might become useful in areas where triclabendazole resistance is common.

show abstract

Resistance of Fasciola hepatica to triclabendazole and albendazole in sheep in Spain

Cited by 122 publications

References 3 publications

Adult triclabendazole-resistantFasciola hepatica: morphological changes in the tegument and gut followingin vivotreatment with artemether in the rat model

Adult triclabendazole-resistantFasciola hepatica: morphological changes in the tegument and gut followingin vivotreatment with artemether in the rat model

Efficacy of a Single Oral Dose of Oxfendazole against Fasciola hepatica in Naturally Infected Sheep

Activity of artemether and OZ78 against triclabendazole-resistant Fasciola hepatica

Contact Info

Product

Resources

About